Delayed graft function (DGF) is a set of unfavorable conditions that starts with inflammation after a cadaveric kidney transplant and can cause damage to a newly implanted kidney–and even force the patient to return to dialysis. Now a Tokyo company (Y’s Therapeutics) is conducting the first clinical trial of YSPSL, a substance that has been shown in animal models to block a type of molecule (P-selectin) from binding to its receptors on the white blood cells–which is a first step in inflammation–and thus hopefully prevent delayed graft function.
Preventing adhesion of molecules. Such a seemingly small thing that makes it clear why science must proceed in the tiniest ways toward the even the greatest discoveries. Read and listen to more about delayed graft function .here